Question 1: Please refer to the underlined (Q1) in the text. Please explain specifically "the experimental therapy"

Answer:

• Standard chemotherapy with trastuzumab (for HER2 positive breast cancer).

Question 2: Please refer to the underlined (Q2) in the text. Please explain what is unstratified.

Answer:

- (Lung cancer patients who are) not stratified by EGFR mutations.
- (Lung cancer patients who are) not selected by *EGFR* mutations.
- Not to be selected by *EGFR* mutations (biomarker)

Question 3: Please refer to the underlined (Q3) in the text. Please explain the notion or idea which is described as "a wakeup call echoing the experience with trastuzumab."

Answer:

Selection on the basis of a biomarker can predict the clinical utility of a targeted anticancer agent and lead to demonstration of efficacy.

Question 4: Please refer to the underlined (Q4) in the text. Please explain what kind of treatment was given to what kind of patients for achievement of the clinical efficacy.

Answer:

Crizotinib was given to lung cancer patients with EML4-ALK rearrangement.

Crizotinib for the treatment of EML4-ALK positive lung cancer patients

Treatment of Crizotinib for lung cancer patients whose tumor has EML4-ALK rearrangement.

Question 5: Please refer to the underlined (Q5) in the text. Please explain what is other issues according to the text, which must be achieve the goal of developing personalized cancer therapies benefiting patients as quickly as possible.

Answer:

To discover experimental tools (genetic and genomic sequence) to (quickly, or simultaneously) identify multigene alteration

Question 6: Please explain how is written in the text about the therapeutic utility of the result form the full-length sequencing of multiple targeted gene.

Answer:

(The therapeutic utility is that) the test results may be used to recommend participation in a particular clinical trial, or the clinician may advise off-label administration of a relevant drug already approved for use against another target.